Off to a strong start with $102 million in series A money, Gritstone Oncology Inc.'s research with immunotherapies based on tumor-specific neoantigens (TSNAs) will first try the vaccine strategy in non-small-cell lung cancer (NSCLC) – a "big idea that merits some detailed attention and effort," CEO, president and co-founder Andrew Allen told BioWorld Today.